Vivo Capital, LLC Kal Vista Pharmaceuticals, Inc. Transaction History

Vivo Capital, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$4.2 - $14.24 $2.85 Million - $9.65 Million	-677,551 Reduced 44.18%	856,008 $5.79 Million
Q4 2021 Feb 11, 2022	SELL	$12.36 - $18.28 $1.34 Million - $1.98 Million	-108,354 Reduced 6.6%	1,533,559 $20.3 Million
Q3 2021 Nov 15, 2021	SELL	$17.11 - $24.49 $3.79 Million - $5.42 Million	-221,383 Reduced 11.88%	1,641,913 $28.7 Million
Q1 2021 May 17, 2021	BUY	$14.69 - $42.57 $3.6 Million - $10.4 Million	245,000 Added 15.14%	1,863,296 $47.9 Million
Q4 2020 Feb 16, 2021	BUY	$12.88 - $19.47 $1.82 Million - $2.76 Million	141,500 Added 9.58%	1,618,296 $30.7 Million
Q1 2020 May 15, 2020	BUY	$5.8 - $18.56 $8.57 Million - $27.4 Million	1,476,796 New	1,476,796 $11.3 Million
Q3 2019 Nov 13, 2019	SELL	$11.6 - $21.67 $15.8 Million - $29.5 Million	-1,359,149 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$8.0 - $22.11 $8.47 Million - $23.4 Million	1,058,824 Added 352.56%	1,359,149 $30.1 Million
Q3 2017 Nov 13, 2017	BUY	$5.84 - $8.88 $1.75 Million - $2.67 Million	300,325	300,325 $2.02 Million

125

47.8M

551K

110K

Ticker KALV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,602,000
Market Cap $250M
Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral p...

Get notified when there are updates to the investment portfolio of Vivo Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Vivo Capital, LLC with notifications on news.